Developing Innovative High-Impact Therapeutic Solutions that Address Major Unmet Needs in Healthcare

Learn More

Orchestra BioMed is a Healthcare Innovation Company

Orchestra BioMed is a biomedical innovation company focused on developing high-impact therapeutic solutions to address significant unmet needs in cardiovascular health and other areas. We specialize in developing novel therapies that are:

  • Designed to fit current clinical treatment paradigms and leverage the established procedural techniques well-known to interventional physicians; and
  • Based on the use as well as convergence of advanced medical technology, biopharmaceuticals, biomaterials-based drug delivery, and intelligent bioelectronic therapeutic algorithms

Our business model is designed to advance promising therapeutic solutions through development and aims to leverage strategic partnerships with established global commercial leaders to optimize commercialization and profitability. The Orchestra BioMed team of industry leaders has proven expertise in every phase of medtech and biopharma product development. Our primary focus on cardiovascular disease reflects our goal to rapidly advance disruptive solutions that will improve the standard of care for millions of patients worldwide.

Product Pipeline Overview

Advancing a deep, multi-asset pipeline of high-impact therapeutic solutions built around two technology platforms.

Learn More

News & Events

Orchestra BioMed™ Strengthens Management Team with Appointments of Expert Product Development Leaders Juan A. Lorenzo and Paul V. Goode, Ph.D.

October 16, 2019

New Hope, PA, October 16, 2019 – Orchestra BioMed,Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine, today announced senior-level appointments to its product development teams. Juan Lorenzo, an expert in vascular devices, joins as vice president, product development, Focal Therapies and will play a leadership role in the development of the Virtue® Sirolimus-Eluting Balloon (SEB) for which the Company has a global strategic partnership with Terumo Corporation. Paul Goode, Ph.D., an expert in implantable neuromodulation devices joins as vice president, product development, Bioelectronic Therapies and will play a leadership role in the further development of BackBeat Cardiac Neuromodulation Therapy (CNT) for which late-breaking double-blind, randomized clinical results recently presented at TCT 2019 demonstrated a statistically significant impact on 24-hour ambulatory systolic blood pressure.

Orchestra BioMed Announces Late-Breaking Clinical Results Showing BackBeat Cardiac Neuromodulation Therapy™ Drives Significant Reduction in Systolic Blood Pressure

September 28, 2019

Double-blind, randomized trial data demonstrates clinically meaningful and statistically significant difference of 8.1 mmHg in reduction of 24-hour ambulatory systolic blood pressure at 6 months vs. control

High responder rate despite 88.5% of treated patients having isolated systolic hypertension (ISH)

Primary safety endpoint achieved with no difference in major cardiac adverse events (MACE) or other cardiac parameters between the two groups at 6 months

Read All News